More interestingly, in patients that relapsed, the addition of entospletinib to VDA significantly increased the percentage of dead cells compared to VDA (p = 0.05) or to entospletinib (p = 0.0003) alone, highlighting the ability of SYK inhibition to sensitize leukemia cells to conventional drugs. Here, SYK is linked to leukemia.